Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

NCT01462578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelocytic Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine

Sponsor

Technische Universität Dresden